by
zydus » Tue Sep 13, 2005 8:46 pm
hi everybody,
normally for validation of a formulation, specificity is done during validation only not during development. i feel it should be check during development .if the specificity fails then it comes back to the development team . if it is done before validation during the development it will save time , money and man power. i am new to this feild , is my argument worth.
regard
zydus
dear frens,
i dont mean that the formulation should be according to analyst convinient. we always try to minimise the risks of failing a method.if the placebo interferes with analyte then its the duty of development team to develop again a new methods. as far as specificity is concern we take longer time to develop unlike other parameter. so i just feel to evaluate it before transfering to the validation team so that there will be less chances of failure.
lastly thanx everybody for sugestion